Subcutaneous immunotherapy for cancer can cause many of the same side effects as intravenous (IV) immunotherapy because it involves the same medications. Injection site reactions are a common but ...
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
(MENAFN- GlobeNewsWire - Nasdaq) SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient ...
“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results